Stiripentol

Stiripentol

Clinical data
Routes of administration	Oral
ATC code	N03AX17 (WHO)
Identifiers
IUPAC name 4,4-dimethyl-1-[3,4(methylenedioxy)-phenyl]-1-penten-3-ol
CAS Number	49763-96-4
PubChem CID	5311454
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H18O3
Molar mass	234.30 g·mol−1

WikiDoc Resources for Stiripentol
Articles
Most recent articles on Stiripentol Most cited articles on Stiripentol Review articles on Stiripentol Articles on Stiripentol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Stiripentol Images of Stiripentol Photos of Stiripentol Podcasts & MP3s on Stiripentol Videos on Stiripentol
Evidence Based Medicine
Cochrane Collaboration on Stiripentol Bandolier on Stiripentol TRIP on Stiripentol
Clinical Trials
Ongoing Trials on Stiripentol at Clinical Trials.gov Trial results on Stiripentol Clinical Trials on Stiripentol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Stiripentol NICE Guidance on Stiripentol NHS PRODIGY Guidance FDA on Stiripentol CDC on Stiripentol
Books
Books on Stiripentol
News
Stiripentol in the news Be alerted to news on Stiripentol News trends on Stiripentol
Commentary
Blogs on Stiripentol
Definitions
Definitions of Stiripentol
Patient Resources / Community
Patient resources on Stiripentol Discussion groups on Stiripentol Patient Handouts on Stiripentol Directions to Hospitals Treating Stiripentol Risk calculators and risk factors for Stiripentol
Healthcare Provider Resources
Symptoms of Stiripentol Causes & Risk Factors for Stiripentol Diagnostic studies for Stiripentol Treatment of Stiripentol
Continuing Medical Education (CME)
CME Programs on Stiripentol
International
Stiripentol en Espanol Stiripentol en Francais
Business
Stiripentol in the Marketplace Patents on Stiripentol
Experimental / Informatics
List of terms related to Stiripentol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Stiripentol (marketed as Diacomit by Laboratoires BIOCODEX) is an anticonvulsant drug used in the treatment of epilepsy. It is unrelated to other anticonvulsants and belongs to the group of aromatic allylic alcohols.

Mechanism of action

As with most anticonvulsants, the precise mechanism is unknown. It has been shown to have anticonvulsant effects on its own. It can prevent the reuptake of GABA and inhibit its metabolism.

It also improves the effectiveness of many other anticonvulsants, possibly due to it inhibiting certain enzymes. This slows the drug's metabolism, increasing blood plasma levels.

Approval history

E.U.

• December 2001 - Treatment of severe myoclonic epilepsy in infancy (SMEI). EU orphan designation number EU/3/01/071.

Stiripentol has very limited availability.

Indications and usage

It is indicated as an adjunctive therapy with sodium valproate and clobazam for treating severe myoclonic epilepsy in infancy (SMEI, also know as Dravet's syndrome). Children with SMEI develop often intractable seizures during their first year of life and mental retardation follows. Small-scale trials have show remarkably high response rates, with a significant minority of those treated becoming seizure free.

In addition, it may be used to treat refractory childhood epilepsy in conjunction with carbamazepine. It appears to be less effective in adolescents and adults.

Dosing

Stiripentol is available as a gelatine capsule (250mg, 500mg) and as a sachet of powder to make a drinkable suspension (250mg, 500mg).

Initial dose is 50 mg/kg per day. This may be increased up to 100 mg/kg per day, with a maximum of 4g. The dose to be divided into two or three with meals. The does of other anticonvulsants may have to be reduced (possibly up to 50%).

Side effects

Side effects are largely due to the increase in plasma concentrations of other anticonvulsants and can be reduced by lowering the does of those drugs. Nausea and vomiting are particularly noted when used in combination with sodium valproate.

Drug interactions

Stiripentol inhibits several cytochrome P450 isoenzymes and so interacts with many anticonvulsants and other medicines. This is both a strength and weakness. It appears to increase the potency of phenobarbital, primidone, phenytoin, carbamazepine, clobazam and diazepam. For example, blood levels of carbamazepine can be maintained whist reducing the dose by 50%.

References

• Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children.

Tran A, Vauzelle-Kervroedan F, Rey E, Pous G, d'Athis P, Chiron C, Dulac O, Renard F, Olive G. (1996)

[Abstract]. European Journal Clinical Pharmacology. 1996;50(6):497–500.

• Stiripentol: efficacy and tolerability in children with epilepsy.

Perez J, Chiron C, Musial C, Rey E, Blehaut H, d'Athis P, Vincent J, Dulac O. (1999)

[Abstract]. Epilepsia. 1999 Nov;40(11):1618–26.

• Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial.

C. Chiron, M. Marchand, A. Tran, E. Rey, P. d'Athis, J. Vincent, O. Dulac, G. Pons. (2000)

[Abstract]. The Lancet 2000 Nov 11, Volume 356, Issue 9242, Pages 1638–1642

• Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome)

Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, Dulac O. (2002)

[Abstract]. Arch Pediatr. 2002 Nov;9(11):1120–7.

• Stiripentol

Chiron C. (2005)

[Abstract]. Expert Opinion on Investigational Drugs July 2005, Vol. 14, No. 7, Pages 905–911]

• Stiripentol. A novel antiepileptic drug

Trojnar MK, Wojtal K, Trojnar MP, Czuczwar SJ. (2005)

[Full Text]. Pharmacological Reports, 2005, 57, 154-160

• Diacomit: Summary of Product Characteristics (Article in French).
• The Comparative Toxicogenomics Database: Stiripentol

External links

• Laboratoires BIOCODEX